The analgesic properties of intravenous pethidine and pethidine plus levallorphan were compared in a group of seventy-two fit obstetric patients. The assessment was made by graded pressure on the tibia. A double blind four-point assay plus placebo technique was used. The trial failed to distinguish between the analgesic effect of the narcotic and the placebo. It is concluded that this method of assessment is inapplicable to the pregnant patient. The commonest side effect noted was dizziness but the incidence of side effects was related more to increased dosage of drugs rather than differences between pethidine and pethidine plus levallorphan.
The combination of levallorphan with pethidine in the ratio of 1:80 was introduced in an attempt to abolish the respiratory depressant effects of pethidine without affecting its analgesic properties (Bullough, 1960) . However, it is doubtful whether these analgesic properties do remain unaffected (Mushin, 1960) . Previous evaluations on patients suffering from various degrees of postoperative pain have relied on the patients' own descriptions of relief or on independent clinical assessment using artificial scoring methods; but the validity of these methods of evaluating analgesic drugs has also been questioned (Beecher, 1957) . It was decided, therefore, to investigate the analgesic effects of pethidine and pethidine plus levallorphan and to compare them with a placebo, using an objective quantitative method for measuring pain threshold.
METHOD
Five groups of 13-15 healthy young women in the last trimester of pregnancy were studied. All had been admitted to hospital for bed rest following complications of pregnancy and were convalescent after pyelitis of pregnancy, toxaemia of pregnancy, or awaiting Caesarean section or delivery of multiple pregnancies. The aims of the trial, the method of assessment and the posPresent address: Anaesthesia Research, Providence Hospital, Seattle, Washington, U.S.A. sible side effects were explained to each patient before her consent was obtained, although the patient remained unaware of the nature of the drug injected. Only one injection was given to each patient, as crossover experiments involving narcotics could not be justified.
The drugs under trial were dissolved in 2 ml of saline and sealed in coded ampoules, as was the placebo itself. The code was not broken until the trial had been completed. Pethidine 50 mg and 100 mg was used alone and combined with levallorphan 0.625 mg and 1.25 mg to maintain the 80:1 ratio.
Pain threshold determinations were made by graded pressure on the tibia using the method first described by Clutton-Brock (1957) and developed by Dundee and Moore (1960) . Contact was made by a flat disc 1 cm in diameter over the subcutaneous bone of the upper end of the tibia. Pressure was applied at the rate of 2 lb. per 5 seconds until the patient complained of discomfort. Two determinations were made and if they agreed within 0.5 lb. the investigation was continued. The drug was then given intravenously over 10 seconds. The patient then remained lying propped on two or three pillows until completion of all observations. Three pain threshold determinations were made, the first at 5, the second at 10, and the third at 30 minutes after drug administration; immediately prior to the pain threshold determination the systolic blood pressure was measured by auscultation using a mercury sphygmomanometer. In addition all subjective sensations experienced by the patient were recorded. These were nausea, dizziness, euphoria and drowsiness. All observations were recorded by one person (P.J.T.). In this way a four-point double blind assay technique was performed and the results were compared with those obtained from the placebo.
The Student "t" test was used as the test of significance for changes in the pain threshold and the yf test of significance used for the other observations.
RESULTS
The control values for pain threshold for all five groups of patients did not differ statistically (table I) . At no time after administration of the placebo was the • pain threshold significantly raised. The pain threshold was raised significantly by pethidine 50 mg 10 minutes after injection (t = 2.47; 0.05>P>0.02) but not 5 minutes after injection (t = 1.226; 0.3>P>0.2) or 30 minutes after injection (t=0.27; P>0.9). Pethidine 100 mg raised the pain threshold significantly both at the 5-minute time (t = 3.251; 0.01 >P>0.001) and at the 10-minute time (t=2.270; 0.05>P>0.02), but not at the 30-minute time (t= 1.225; 0.3>P>0.2). Pethidine 50 mg combined with levallorphan 0.625 mg produced the greatest elevation of pain threshold though this reached statistically significant levels only at the 5-minute time (t = 5.868; 0.001>P) and the 10-minute time (t = 2.544; 0.05>P>0.02) and not at the 30-minute time (t= 1.676; 0.2>P>0.1). Pethidine 100 mg combined with levallorphan 1.25 mg at no time raised the pain threshold significantly above the control value, the value at the 5-minute rime for t being 1.910 (0.1>P> 0.05). At 10 minutes this was t = 1.213 (0.3>P >0.2) and at 30 minutes it had fallen to t = 0.513 (0.7>P>0.6).
The dose response curves show an increased response, as witnessed by elevation of pain threshold, with increased doses of pethidine 5 minutes and 30 minutes after injection, but not 10 minutes after drug administration. The dose response curves after pethidine combined with levallorphan showed a decreased response at all times that the response was measured ( fig. 1 ). Changes in pain threshold in five groups of patients, each receiving saline or pethidine, or pethidine plus levallorphan intravenously. All figures are in lb. pressure, applied over an area 1 cm in diameter. + = standard deviation.
• = statistically significant elevation above control value for that group (P<0.05). All subsequent readings made singly for each patient at each of the specified times. Changes in pain threshold with increased dosage of intravenous pethidine and pethidine plus levallorphan. Values represent averages obtained from groups of 13-15 patients.
PETfflDINE COMPARED WITH PETHIDINE PLUS LEVALLORPHAN
The time response curves showed, after an initial elevation of pain threshold 5 minutes after drug administration, a decreasing effect with time for both doses of pethidine plus levallorphan and with pethidine 100 mg alone. The decrease in response did not occur until at least 10 minutes following both pethidine 50 mg and the placebo (fig 2) .
When all the drugs are compared with the placebo (table I) only pethidine 50 mg with levallorphan 0.625 mg, 5 minutes after injection, by raising the pain threshold 2.76 lb. ± 1.82, raised it significantly above the 0.75 ± 2.09 elevation produced by the placebo (t = 2.808; 0.01> P>0.001). Apart from this result there was no statistical difference between the effect of the drugs on pain threshold and the effect of the placebo. This contrasted markedly with the effect of giving a drug and the corresponding group's control observations, when all the drugs except pethidine 100 mg with levallorphan 1.25 mg produced statistically significant increments initially on the pain threshold. Even when all the results are pooled together from both doses of both drugs, from both the 5-minute and 10-minute observations, giving 114 observations from 57 patients with a mean elevation of pain threshold of 1.63 lb. ± 2.56 lb., and this is compared with a mean of 1.00 ± 2.30 lb. obtained from the 30 observations made at the same times from the 15 patients given the placebo, there is no statistically significant difference (t= 1.295; 02> Pethidine 50 mg with levallorphan 0.625 mg raised the pain threshold significantly above the level produced by pethidine 50 mg at the 5-minute time (t = 2.064; 0.05>P>0.02). Apart from this no drug or dose was significantly better than the others.
Blood pressure and subjective effects.
Fifty-seven of the seventy-two patients in this trial received either pethidine or pethidine plus levallorphan intravenously. The drugs were given over 10 seconds. No patient developed clinically significant hypotension. There was no difference in the mean systolic arterial pressure of each group, at any time (table II) .
The number of patients who experienced dizziness, nausea, vomiting, euphoria and drowsiness is shown in table HI. No other side effect was noted by the patients. Dizziness was the most common side effect noted. This dizziness was was always described as vertical, in that the horizon oscillated vertically. It would be experienced within 2 minutes of administering the drug and it lasted up to 10 minutes.
The drugs could be distinguished statistically from the placebo by the incidence of side effeas. The only side effect noted in those patients re- ceiving the placebo occurred in one patient who became euphoric, though all patients were warned that they might feel so after the intravenous injection. This low incidence of side effects in those patients given the placebo may be compared with the incidence of side effects in the 57 patients receiving a narcotic, 51 of whom developed one or more side effect.
There was a significant difference in the incidence of side effects noted between those patients given the large doses of narcotic and those who received a small dose of narcotic (P<0.005). There was no difference in the incidence of side effects noted between those patients who received narcotics in the same dose range, nor was there any significant difference in the incidence of side effects between those patients who received pethidine only and those who received pethidine plus levallorphan.
DISCUSSION
In a double blind trial designed to assess, by analgesimetry, pethidine alone and pethidine plus levallorphan no differences could be detected when the results were compared with those after a placebo.
The patients taking part in this trial were all young women in late pregnancy. Pregnant patients provide a homogeneous population of the same degree of metabolic activity and age range and this helps reduce the number of variables in a clinical trial. The drugs used in this trial are those recommended for analgesic relief in the obstetric patient but objective data of their comparative efficacy in such patients is lacking.
The addition of levallorphan to pethidine in the 1:80 ratio is claimed not to affect its analgesic properties (Bullough, 1960) . This presents some difficulty in interpreting results when a levallorphan pethidine mixture is compared with pethidine. Failure to detect any difference in drug response in a clinical trial involving near equipotent drugs is open to two interpretations. Either there is no difference between the two drugs and they really are equipotent or else the trial is too insensitive to detect any differences between the two drugs. If, however, two doses of the standard drugs are used and the method of assessment can discriminate between them, then the unknown should be capable of being distinguished from one of the two doses of the standard. Should the unknown lie between the two doses of the standard then a smaller dose of the unknown should also be used and this should be easily distinguishable from the high dose of the standard if the experimental method is satisfactory. This was the basis for using the fourpoint assay method in this present trial. The addition of a placebo in this trial was to determine the placebo response and check observer error.
The choice of method for assessment of analgesic relief was that described by Clutton-Brock (1957) and developed by Dundee and Moore (I960), the only difference being that in the technique of analgesimetry used in their trials pressure was applied at uniformly increasing rates with respect to time. Notwithstanding the lack of placebos and double blind trials in their publications, these authors have claimed to be able to distinguish objectively between drugs of a similar nature, e.g. the different phenothiazines and the different halogenated hydrocarbons. The method is therefore claimed to have a high level of pharmacological discrimination. However, when, having used this method of assessment, the results of t-hiR trial were analyzed, no difference could be detected. There was no difference in response between the two sets of drugs and no difference in response between two doses of the same drug. This rules out drawing any positive conclusion that the two drugs might be equipotent. But, furthermore, the method of assessment could not distinguish between pethidine 100 mg and the placebo. Even when all the results were pooled together an intravenous dose of analgesic could not be distinguished from an intravenous injection of saline. This would suggest that no valid conclusions can be drawn about the analgesic potency of the drugs used in this trial, but rather that this method of analgesimetry is not applicable at least to the obstetric patient. Thus the inclusion of the placebo in this trial showed that the method of assessment was invalid. Dundee and Moore (1960) , in their first paper describing the use of this method of analgesimetry, suggested that the principal source of error was the observer. The fact that in this present series the five sets of control values agreed so closely would suggest that the observer error was not the major reason for the failure of the trial. Moreover, the use of the double blind technique reduces the chance of observer error influencing the results.
A possible explanation why this assay failed may lie in the population studied. This consisted of young women in late pregnancy. It has been stated (Ransom, 1959 ) that young women in late pregnancy are the most suggestible of all patients. It is possible that the placebo response was so much greater than the specific pharmacological response as to invalidate the study, even though the method of analgesimetry in the non-pregnant patient is claimed to have good discrimination.
The drugs could be distinguished from the placebo by the incidence of side effects. The incidence of side effects, however, was related more to the dose of narcotic than to differences between drugs, and the addition of the antagonist levallorphan to pethidine made little difference to the incidence.
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LA PETHIDINE COMPAREE A LA PETHIDINE PLUS LEVALLORPHAN ET A UN PLACEBO
SOMMAIRE
Dans un groupe de 72 malades d'un service d'obstetrique, on a compari les propriStes analg&iques de la pethidine intra-veineuse, et de la pethidine avec levallorphan. On a apprecie les resultats par une pression graduee sur le tibia. On a utilise l'essai en double insu en quatre points plus la technique du placebo. L'essai n'a pas pennis de distinguer entre l'effet analgesique du narcotique et le placebo. On conclut que cette mdthode devaluation est inapplicable aux femmes enceintes. L'effet secondaire le plus courant etait les vertiges, mais Pincidence des effets secondaires etait en relation davantage avec la posologie augmentee des drogues qu'avec des differences entre la pethidine et la pethidine avec levallorphan. 
